Explain this page
Arphra AIPlain-English read on Incyte Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
- BIIBBiogen Inc.$187.06$27.62B
- UTHRUnited Therapeutics Corporation$570.40$25B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- WSTWest Pharmaceutical Services, Inc.$300.68$21.24B
- RPRXRoyalty Pharma plc$49.47$21.19B
- ILMNIllumina, Inc.$135.78$20.63B
- WATWaters Corporation$307.12$18.28B
- GMABGenmab A/S$26.45$16.3B
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.19% | -1.98% | -1.36% | -5.61% | -6.32% | -3.22% | +46.36% | +55.41% | +15.32% | +12.22% | +4998.13% |
Aftermarket
LiveLast trade
$95.59
4 sh
Bid
$94.30
3 sh
Ask
$99.88
10 sh
Spread
$5.580
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Biotechnology-2.72%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$373.65
+290.88% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
10bull4bear
±5% threshold
Analyst PT consensus: $109.50 (+14.55%)
Total assets
$6.96B
Total debt
$69.43M
Cash & equiv
$3.1B
Operating CF
$1.41B
Free cash flow
$1.35B
Buybacks
-$19.1M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$109.50
+14.55% upside
Low
$90.00
Median
$108.50
High
$135.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congressbusinesswire.com·May 12, 2026
- Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congressbusinesswire.com·May 12, 2026
- Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitisbusinesswire.com·May 07, 2026
- Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com·May 06, 2026
- Why Incyte (INCY) is a Top Momentum Stock for the Long-Termzacks.com·May 04, 2026
- New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]prnewswire.com·May 03, 2026
- Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Diseasebusinesswire.com·May 01, 2026
- Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Diseasebusinesswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.27B | $303.33M | $1.47 |
| Q4 Dec 2025 | $1.51B | $299.28M | $1.46 |
| Q3 Sep 2025 | $1.37B | $424.17M | $2.11 |
| Q2 Jun 2025 | $1.22B | $405M | $2.04 |
| Q1 Mar 2025 | $1.05B | $158.2M | $0.80 |
| Q4 Dec 2024 | $1.18B | $201.21M | $1.02 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
CAGNONI PABLO J officer: President, Global Head of R&D | Sell | 18,667 | $1.8M | Apr 17, 2026 |
CAGNONI PABLO J officer: President, R&D | Sell | 18,667 | $1.76M | Mar 17, 2026 |
CAGNONI PABLO J officer: President, R&D | Sell | 18,668 | $1.88M | Feb 19, 2026 |
Issa Mohamed Khairie officer: EVP, Head of US Oncology | Sell | 10,856 | $1.18M | Jan 07, 2026 |
Stein Steven H officer: EVP & Chief Medical Officer | Sell | 15,634 | $1.59M | Jan 05, 2026 |
Tray Thomas officer: Principal Accounting Officer | Sell | 2,774 | $277.4K | Dec 19, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $5.14B | $1.34B | $1.29B | $6.41 | +25.03% |
| FY 2024 | $4.24B | $80.14M | $32.62M | $0.15 | +0.77% |
| FY 2023 | $3.7B | $651.77M | $597.6M | $2.65 | +16.17% |
| FY 2022 | $3.39B | $599.56M | $340.66M | $1.52 | +10.04% |
| FY 2021 | $2.99B | $637.54M | $948.58M | $4.27 | +31.76% |